Evaluating the safety profile of semaglutide: an updated meta-analysis.

Frederick Berro RiveraEloise Arias-AguirreZedrick AguirreMc John C YbañezJanos Marc M RubiaDanica Janine GalangGrace Nooriza LumbangJade Monica Marie J RuyerasJohn Vincent MagalongPolyn Luz PineJohn Andrew C AmigoMarie Francesca M AnsayNenad ZelenkovSteve Samuel ThomasKrishnaswami Vijayaraghavan

Published in: Current medical research and opinion (2024)

Semaglutide appears to have a favorable safety profile across diverse patient populations and treatment durations, supporting its continued use in the management of type 2 diabetes mellitus and obesity. It is generally well-tolerated, with a low incidence of adverse events. Clinicians should be aware of these findings and monitor patients accordingly. Further long-term studies are warranted to assess the safety of semaglutide in clinical practice.

Keyphrases

systematic review
end stage renal disease
clinical practice
chronic kidney disease
ejection fraction
metabolic syndrome
newly diagnosed
insulin resistance
case control
weight loss
peritoneal dialysis
case report
prognostic factors
palliative care
adipose tissue
weight gain
patient reported outcomes
skeletal muscle